Robert Burns

H.C. Wainwright & Co.

Recent Articles about Replimune Group Inc.

MA Biotech Co. Downgraded to Sell After Second FDA CRL for RP-1 Melanoma BLA 04/13/2026

H.C. Wainwright downgraded Replimune Group (REPL:NASDAQ) to Sell after the FDA issued a second Complete Response Letter for the RP-1 plus Opdivo BLA in anti-PD1 failed melanoma.